DP
GLUE icon

Diadema Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Diadema Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Sell
78,391
-108,916
-58% -$2.06M 0.24% 80
2026
Q1 		$3.08M Buy
187,307
+125,026
+201% +$2.39M 0.52% 49
2025
Q4 		$977K Buy
+62,281
New +$839K 0.17% 93

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Diadema Partners's GLUE Position: Q2 2026 in Review

Diadema Partners reduced its Monte Rosa Therapeutics (GLUE) stake by 58% in Q2 2026, selling an estimated $2.06M and leaving 78,391 shares worth $1.9M. The position accounts for 0.24% of the portfolio, ranked #80.

Diadema Partners first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.08M in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Diadema Partners held 78,391 shares of Monte Rosa Therapeutics worth $1.9M as of Q2 2026.
  • Diadema Partners sold 108,916 Monte Rosa Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Monte Rosa Therapeutics made up 0.24% of Diadema Partners's portfolio in Q2 2026, its #80 holding.
  • Diadema Partners first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Diadema Partners's Monte Rosa Therapeutics position peaked at $3.08M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.